Making rare disease drug development personal
The statistics regarding rare diseases speak for themselves: one of two patients diagnosed with a rare disease is a child; three of 10 children with a rare disease won’t live to see their fifth birthday; more than 400 million people suffer from a rare disease globally — greater than the population of the U.S. Fortunately, the drug development landscape for rare diseases is increasing exponentially. However, there are many challenges in conducting rare disease clinical trials, including small populations often spread across the globe, limited opportunities for study participation and replication of results in larger trials, and heterogeneous manifestations of disease and phenotypic presentations. The clinical manifestations are often not easily connected to a specific disease — on average, a rare disease patient visits seven specialists, and a correct diagnosis can take as long as six to eight years — and a lack of consensus on clinical outcome measures and poorly defined endpoints.
In this article, Shipra Patel, M.D., Global TA Section Head, Endocrinology, Parexel, discusses how she strives to overcome these challenges daily.
Related Insights
Podcast
Enabling Successful Sites, Ep2: Empowering Sites to be More Inclusive Through Cultural Sensitivity Training
Jun 28, 2024
Podcast
De-risking Drug Development | Episode 1: How to drive value in pre-clinical development
May 28, 2024
Blog
Unpacking NICE’s review of the HST routing criteria: implications for manufacturers
Oct 3, 2024
Podcast
Enabling Successful Sites, Ep3: Taking the complexity out of oncology clinical trials
Jun 28, 2024
Podcast
Rare endpoints: Delivering on unmet patient needs
May 7, 2024
Blog
Accelerating Delivery and Patient Access to Rare Disease Treatments – Highlights from World Orphan Drug Congress
May 2, 2024
Blog
Adapting the validation process for PROs for rare diseases and other diseases with large unmet need and/or rapid progression
Apr 23, 2024
Blog
How sponsors can make it easier for rare disease patients and families to participate in trials
Feb 13, 2024
Blog
Studying rare cancer patient populations using integrated genomic and real-world data
Aug 30, 2023
Blog
Celebrating 40 Years of Rare Disease Progress: WODC Highlights
Jun 6, 2023
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Playbook
Insights from the 2022 R&D Innovation Survey
Feb 17, 2023
Related Insights
Podcast
Enabling Successful Sites, Ep2: Empowering Sites to be More Inclusive Through Cultural Sensitivity Training
Jun 28, 2024
Podcast
De-risking Drug Development | Episode 1: How to drive value in pre-clinical development
May 28, 2024
Blog
Unpacking NICE’s review of the HST routing criteria: implications for manufacturers
Oct 3, 2024
Podcast
Enabling Successful Sites, Ep3: Taking the complexity out of oncology clinical trials
Jun 28, 2024
Podcast
Rare endpoints: Delivering on unmet patient needs
May 7, 2024
Blog
Accelerating Delivery and Patient Access to Rare Disease Treatments – Highlights from World Orphan Drug Congress
May 2, 2024
Blog
Adapting the validation process for PROs for rare diseases and other diseases with large unmet need and/or rapid progression
Apr 23, 2024
Blog
How sponsors can make it easier for rare disease patients and families to participate in trials
Feb 13, 2024
Blog
Studying rare cancer patient populations using integrated genomic and real-world data
Aug 30, 2023
Blog
Celebrating 40 Years of Rare Disease Progress: WODC Highlights
Jun 6, 2023
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Playbook
Insights from the 2022 R&D Innovation Survey
Feb 17, 2023